https://finance.yahoo.com/news/seagen-lava-therapeutics-announce-exclusive-120000733.html
0
0
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors - Yahoo Finance
9/26/22 at 12:00pm
Organization
Yahoo Entertainment
Author
Business Wire
Details
49 words
Summarize
Pharmaceuticals & Biotech Business & Industrial LAVA Therapeutics Announce Exclusive Worldwide License Agreement Seagen Wash Yahoo Finance BOTHELL Preclinical Gamma Delta Bispecific T Cell Engager world leader Utrecht PHILADEPHIA Dutch antibody-drug conjugate Nasdaq SGEN
BOTHELL, Wash. & UTRECHT, Netherlands & PHILADELPHIA, September 26, 2022--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (...
Create an account or login to join the discussion